NCT00081861View on ClinicalTrials.gov

Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

Lymphoma

Interventions

DRUG

Avastin

10 mg/kg given intravenously every 2 weeks for 4 doses.

DRUG

Rituximab

375 mg/m\^2 given intravenously weekly for 8 doses, 30 minutes to 1 hour following Bevacizumab.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER